Streamlining Gastroenterology Prior Authorizations with Magellan Healthcare

Klivira optimizes prior authorization workflows for gastroenterology practices navigating Magellan Healthcare's utilization management processes.

Gastroenterology (GI) practices face a high volume of prior authorizations, particularly for high-cost biologics, advanced imaging, and complex procedures. Managing these submissions with utilization management entities like Magellan Healthcare, a Centene company, requires precision and adherence to specific clinical criteria to minimize denials and ensure timely patient care. Klivira’s platform is engineered to address these challenges.

High-Volume PA Categories in Gastroenterology for Magellan Submissions

Prior authorization burden in gastroenterology is concentrated in several key areas. These include biologics for inflammatory bowel disease (IBD) such as Humira, Stelara, Skyrizi, and Entyvio, which often require chronic re-authorization. Additionally, advanced imaging like MR enterography and specific endoscopic procedures, along with specialty IBD drugs, frequently trigger PA requirements when submitted to Magellan Healthcare.

Common Gastroenterology PA Triggers for Magellan Healthcare

IBD biologics (e.g., TNF inhibitors, integrin inhibitors, IL-12/23 inhibitors, JAK inhibitors)
Hepatitis C direct-acting antivirals (e.g., sofosbuvir-velpatasvir, glecaprevir-pibrentasvir)
Advanced imaging (e.g., MRCP, MR enterography, CT enterography)
Endoscopic procedures (e.g., capsule endoscopy CPT 91110, ERCP, EUS)
Specialty drugs for functional GI disorders (e.g., eluxadoline, prucalopride)
Non-routine colonoscopy screening exceptions

Navigating Magellan Healthcare's Documentation Requirements with Clinical Guidelines

Magellan Healthcare's utilization management adheres to clinical guidelines from bodies such as ACG, AGA, and AASLD. For IBD biologics, this often means requiring documented disease severity (Mayo score, CDAI), prior conventional therapy trials, and TB/hepatitis screening. For Hepatitis C DAAs, genotype, fibrosis stage, and prior treatment history are critical. Klivira's platform integrates these guideline-driven documentation requirements, facilitating accurate and complete submissions to Magellan.

Frequent GI Prior Authorization Denial Reasons with Magellan

Failure to meet step therapy requirements for IBD biologics (e.g., conventional therapy trial, biosimilar first)
Insufficient documentation of disease severity (e.g., missing Mayo score or CDAI)
Gaps in required pre-treatment screenings (e.g., TB, hepatitis) for biologics
Inappropriate-use criteria for advanced imaging requests lacking clinical correlation
Incomplete prior workup or indication not meeting policy for capsule endoscopy

Klivira's Approach to Gastroenterology PA Automation for Magellan

Klivira addresses the unique workflow constraints of gastroenterology, such as the chronic PA burden for IBD biologics and the variability in biosimilar substitution policies. Our system incorporates ACG/AGA-guideline-aware step therapy logic, automates treatment-status classification from EMR medication history, and manages periodic re-authorization workflows. This ensures that submissions to Magellan Healthcare are consistent, complete, and aligned with their specific UM criteria.

Optimizing EMR and Payer Touchpoints for Magellan Submissions

Our platform integrates seamlessly with major EMR systems to capture necessary clinical data for GI prior authorizations. This includes pulling relevant order types for biologics, imaging, and procedures, along with clinical template data for disease severity and prior therapies. Klivira then routes these comprehensive data sets through appropriate payer channels, including X12 278 transactions or payer portals, ensuring efficient communication with Magellan Healthcare and reducing manual data entry.

Frequently asked questions

How does Klivira manage step therapy requirements for IBD biologics when submitting to Magellan Healthcare?

Klivira incorporates ACG/AGA-guideline-aware step therapy logic to guide submissions for IBD biologics. Our system helps identify and document prior conventional therapy trials or required biosimilar substitutions, ensuring that the necessary steps are met before submitting to Magellan Healthcare's utilization management.

What specific documentation does Magellan Healthcare typically require for advanced GI imaging, and how does Klivira facilitate this?

For advanced GI imaging like MR enterography, Magellan typically requires documentation of the clinical question, prior imaging history, and completion of conservative evaluation workup. Klivira's platform helps gather and organize this specific clinical data from the EMR to ensure comprehensive submissions that meet Magellan's medical necessity criteria.

How does the medical vs. pharmacy benefit split affect prior authorizations for GI drugs submitted to Magellan, and how does Klivira handle it?

Many GI biologics can be administered under either medical or pharmacy benefits, complicating PA workflows. Klivira's system is designed to route submissions appropriately based on the administration mode (provider-administered infusion vs. self-administered injection), ensuring correct benefit classification when interacting with Magellan Healthcare.

Can Klivira automate re-authorizations for chronic GI conditions like IBD with Magellan Healthcare?

Yes, Klivira provides a periodic re-authorization workflow specifically for chronic-treatment biologics used in IBD. Our platform tracks re-authorization cycles and prompts for necessary updated documentation of disease response, streamlining the ongoing PA process with Magellan Healthcare.

How does Klivira help prevent denials related to missing screening documentation for GI biologics submitted to Magellan?

Klivira's platform integrates checks for critical pre-initiation screenings, such as TB and hepatitis, required for IBD biologics. By highlighting these documentation requirements and facilitating their inclusion in the submission, Klivira helps prevent common denial reasons from Magellan Healthcare.